Today: 30 April 2026
Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR
12 January 2026
1 min read

Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR

NEW YORK, Jan 12, 2026, 15:12 EST — Regular session

  • Lululemon shares climbed in afternoon trading following the retailer’s update that its holiday-quarter results are expected to come in near the high end of its previous forecast
  • The company held steady on its margin and expense forecasts
  • Focus shifts to ICR conference meetings amid ongoing CEO search

Shares of lululemon athletica inc climbed roughly 3.2% to $210.43 Monday afternoon. The boost came after the company forecasted its fourth-quarter revenue and profit to hit the upper end of its previous guidance, driven by strong holiday demand.

This update is crucial since the stock has acted as a barometer for confidence. Investors have been on edge, looking for clear evidence that demand isn’t weakening further while the company works on revamping its U.S. operations.

This comes as management faces intense scrutiny from analysts and major shareholders, with the company’s strategy and leadership transition still unresolved.

Lululemon now projects fourth-quarter fiscal 2025 net revenue and diluted earnings per share to land near the top of its prior guidance. The company expects revenue between $3.500 billion and $3.585 billion, with EPS ranging from $4.66 to $4.76. CFO Meghan Frank pointed to the holiday season as the reason they’re targeting the “higher end” of those estimates. Lululemon

That figure aligns closely with Wall Street expectations. Analysts surveyed by RTTNews and featured on Nasdaq’s site project roughly $3.57 billion in revenue and $4.78 in EPS for the quarter.

William Blair’s Sharon Zackfia and team labeled Lululemon a “show-me story,” arguing the spring product cycle will likely drive the stock more than wrapping up the holiday quarter near the top of guidance. Barron’s

Lululemon’s action coincided with declines across other sportswear stocks. Nike dipped roughly 0.9%, Under Armour slid 0.7%, and Deckers Outdoor dropped close to 1.9% in afternoon trading.

The retailer is currently undergoing a CEO transition. Calvin McDonald plans to step down as CEO and board member on Jan. 31. Frank and chief commercial officer André Maestrini will act as interim co-CEOs during the board’s ongoing search, the company announced in December.

Adding fuel to the fire, founder Chip Wilson has kicked off a proxy fight—a shareholder vote to reshuffle board seats. At the same time, activist investor Elliott Management has scooped up about a $1 billion stake, Reuters reported last month.

Monday’s update remains a “within-the-range” note rather than a fresh outlook. The company stuck to its previous guidance on gross margin and operating expenses. Still, heavier promotions to move inventory might squeeze profits, even if sales remain steady. Business Wire

Management will hold a series of meetings at the ICR Conference in Orlando through Jan. 14. Investors are keen to hear updates on U.S. demand, discounting strategies, and progress in the CEO search.

Stock Market Today

  • Defensive Rebalancing Signals Return in Dow Jones and US Stocks at Month-End
    April 30, 2026, 1:19 PM EDT. As the month closes, the Dow Jones and U.S. stock markets are showing signs of defensive rebalancing-a strategy where investors shift towards safer assets to buffer potential volatility. Market analyst Elior Manier, with over seven years in finance and expertise in geopolitical and macroeconomic factors, highlights the resumption of this trend amid recent breaking news and economic data releases. Manier's experience as a fixed income trader informs his view that traders are reacting to a mix of market sentiment and technical signals. This shift reflects cautious positioning as investors digest ongoing developments impacting trading flows ahead of the new month.

Latest article

Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

Dow Jones Today: Caterpillar Sparks 700-Point Rally as Wall Street Shrugs Off Oil Shock

30 April 2026
The Dow Jones Industrial Average surged nearly 700 points midday Thursday, driven by a 10% jump in Caterpillar shares after strong quarterly results. The S&P 500 and Nasdaq rose modestly as tech stocks lagged. U.S. GDP grew at a 2% annual rate, but inflation data remained above the Fed’s target, limiting rate-cut expectations. Industrials outperformed, while some major tech firms fell on capex concerns.
Dow Jumps 700 Points as US Stock Market Today Shrugs Off Oil Shock and Chases Best Month Since 2020

Dow Jumps 700 Points as US Stock Market Today Shrugs Off Oil Shock and Chases Best Month Since 2020

30 April 2026
The Dow Jones rose 1.48% to 49,584.97 by midday Thursday, outpacing the S&P 500 and Nasdaq as strong corporate earnings pushed major indexes toward their best monthly gains since 2020. First-quarter GDP grew at a 2.0% annual rate, while the core PCE price index climbed 4.3%. The Federal Reserve held rates steady, citing persistent inflation. Alphabet’s Google Cloud revenue surged 63%, while Meta and Microsoft announced large AI-driven spending plans.
Hertz Stock Surges on Uber Robotaxi Deal as Oro Mobility Steps Out of the Shadows

Hertz Stock Surges on Uber Robotaxi Deal as Oro Mobility Steps Out of the Shadows

30 April 2026
Hertz shares surged over 20% Thursday after it launched Oro Mobility, an affiliate set to manage Uber’s robotaxi and human-driven fleets in key U.S. markets. Oro will support Uber’s autonomous program with Lucid vehicles using Nuro self-driving tech, starting in the San Francisco Bay Area later this year. Hertz traded at $6.80, up $1.20; Uber fell 38 cents to $74.09. Hertz reports first-quarter results May 7.
Salesforce stock gets new Goldman Buy call — here’s the next catalyst for CRM
Previous Story

Salesforce stock gets new Goldman Buy call — here’s the next catalyst for CRM

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows
Next Story

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Go toTop